Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
59.10
+1.69 (+2.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,741,392
Open
58.09
Bid (Size)
58.55 (1)
Ask (Size)
59.30 (1)
Prev. Close
57.41
Today's Range
57.41 - 59.15
52wk Range
32.83 - 59.15
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
August 08, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
Performance
YTD
+58.06%
+58.06%
1 Month
+7.26%
+7.26%
3 Month
+30.20%
+30.20%
6 Month
+64.58%
+64.58%
1 Year
+36.52%
+36.52%
More News
Read More
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
August 08, 2024
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
August 06, 2024
Via
Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
August 01, 2024
Via
Benzinga
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
July 22, 2024
Via
Chartmill
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
Via
Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
August 05, 2024
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
August 04, 2024
Via
InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
Via
Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
July 18, 2024
Via
InvestorPlace
NASDAQ:HALO is showing good growth, while it is not too expensive.
July 18, 2024
Via
Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
July 16, 2024
Via
Benzinga
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
July 15, 2024
Via
Chartmill
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
Via
Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Via
Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
July 15, 2024
Via
InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
July 12, 2024
Via
Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
July 09, 2024
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.